drugset / Trial / NCT01454180
Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets
Phase 2
Completed
31 enrolled
Spanish National Cancer Research Centre
Apices Soluciones S.L. · collabGrupo Hospital de Madrid · collabHospital Universitario de Fuenlabrada · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the proportion of patients alive after 12 months of the beginning of the trial in patients with advanced pancreatic carcinoma individually selected and grouped according to the expression in tumor tissue for therapeutic targets.
Timeline
- Start
- 2011-10
- Primary completion
- 2011-10
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 5'Fluouracilo | Unknown | 400 mg/m2 | Intravenous |
| Comparator | 5'Fluouracilo | Unknown | 2400 mg/m2 | Intravenous |
| Comparator | Capecitabine | Small molecule | 830 mg/m2 | Oral |
| Comparator | Erlotinib | Small molecule | 100 mg | Oral |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Comparator | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Comparator | Leucovorin | Small molecule | 400 mg/m2 | — |